The latest National Comprehensive Cancer Network (NCCN) guidelines for NSCLC recommend replacing traditional chemotherapies with ICIs-containing regimens as the preferred first-line therapies for NSCLC when PD-L1 expresses in at least 50% of tumor cells (National Comprehensive Cancer Network, 2021). This evidence concerns the gene CD274 and non-small cell lung carcinoma.